
|Articles|December 3, 2018 (Updated: December 20, 2020)
Novel treatments in pipeline for diabetic eye disease
Patrik De Haes, MD, CEO of Oxurion NV, shares the latest updates in clinical studies at the OIS@AAO meeting in Chicago, Oct. 2018.
Advertisement
Patrik De Haes, MD, CEO of Oxurion NV, shares the latest updates in clinical studies at the OIS@AAO meeting in Chicago, Oct. 2018.
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
The Retina TL;DR with Dr. Weng: Tracking retinal gene therapies with Arshad M. Khanani, MD, MA, FASRS
2
Q&A: AI-predicted retinal function shows promise in geographic atrophy
3
Dr. Mali’s top 5 predictions in ophthalmology for 2026
4




























